[18F]FAPI PET/CT in Suspicious Focal Liver Lesions Without FDG Avidity
Study Details
Study Description
Brief Summary
Fibroblast activation protein (FAP) is a serine protease that belongs to the dipeptidyl peptidase-IV (DPP-IV) family located in fbroblast membranes. FAP is overexpressed in the cancer-associated fbroblasts (CAFs) of 90% of epithelial carcinomas, including primary and metastatic liver cancer. We aim to conduct a prospective study to investigate the diagnostic perfoemance of 18F-FAPI PET/CT in evaluating suspicious liver mass without FDG avidity.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Fibroblast activation protein (FAP) is a serine protease that belongs to the dipeptidyl peptidase-IV (DPP-IV) family located in fbroblast membranes. FAP is overexpressed in the cancer-associated fbroblasts (CAFs) of 90% of epithelial carcinomas, including primary and metastatic liver cancer. Therefore, FAP-targeted radiopharmaceuticals can be considered a promising approach for visualizing CAFs. CAFs are crucial components of the tumor stroma, promote the growth of cancer cells, and are associated with poor prognosis. Currently, 18F-labelled fbroblast activation protein inhibitor 18F-FAPI has shown promising diagnostic value in many types of tumors, especially those in which are not avid for 18F-FDF , and several studies have demonstrated that 18F-FAPI PET/CT is superior to 18F-FDG PET/CT for detecting liver cancer and has lower tracer uptake in normal liver tissue. We aim to conduct a prospective study to investigate the diagnostic performance of 18F-FAPI PET/CT in evaluating suspicious liver mass without FDG avidity.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: suspicious focal liver mass without FDG avidity Experimental: 18F-FAPI PET/CT Imaging was performed 30-60 minutes after injection of 2-4mci 68Ga-FAPI tracer |
Diagnostic Test: FAPI PET
Drug: 18F-FAPI 18F-FAPI were injected into the patients before the PET/CT scans
|
Outcome Measures
Primary Outcome Measures
- Diagnostic performance of FAPI PET [1 year]
Sensitivity and specificity in detecting liver cancer
Eligibility Criteria
Criteria
Inclusion Criteria:
-
patients with suspected liver malignant lesions based on traditional diagnostic imaging (CT or MRI or ultrasound) and clinical symptoms;
-
patients underwent [18F]FDG PET/CT with negative findings (suspicious primary and/or metastatic lesions were hypo- or isometabolic on [18F]FDG PET/CT);
-
patients who agreed to undergo [18F]FAPI PET/CT scans within 1 week.
Exclusion Criteria:
-
pregnancy;
-
age<18 years old;
-
patients with chemo/radio/targeted therapy before scanning;
-
inability to provide informed consent (signed by participant, parent, or legal representative).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | China-Japan Union Hospital | Chang chun | Jilin | China | 130031 |
Sponsors and Collaborators
- Jilin University
Investigators
- Principal Investigator: Bin Ji, China-Japan Union Hospital, Jilin University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ChinaJapanUH